392MO Recurrent patient-reported outcome (PRO)-based deterioration predicts overall survival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial
Titel:
392MO Recurrent patient-reported outcome (PRO)-based deterioration predicts overall survival (OS) in patients with advanced gastric adenocarcinoma with PD-L1 score of ≥5%: Results from the RATIONALE-305 trial
Auteur:
Moehler, M. Cruz-Correa, M. Oh, D-Y. Xu, R-H. Kato, K. Barzi, A. Barnes, F.B.B. Xu, Y. Sheng, T. Barnes, G. Victor, T.